Further developments in the literature on RAAS inhibitors and COVID-19.

Authors :: Quinn KL
Fralick M
Zipursky JS
Stall NM
Source :: CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne [CMAJ] 2020 Jun 29; Vol. 192 (26), pp. E727.
Publication Year :: 2020
Abstract: Competing Interests: Competing interests: None declared.

Subjects :: Angiotensin-Converting Enzyme Inhibitors adverse effects
Betacoronavirus
COVID-19
Cardiovascular Agents adverse effects
Critical Care
Humans
Pandemics
Renin-Angiotensin System
Risk Factors
SARS-CoV-2
Angiotensin-Converting Enzyme Inhibitors therapeutic use
Cardiovascular Agents therapeutic use
Cardiovascular Diseases complications
Cardiovascular Diseases drug therapy
Coronavirus Infections complications
Coronavirus Infections mortality
Evidence-Based Medicine
Pneumonia, Viral complications
Pneumonia, Viral mortality

Language :: English
ISSN :: 1488-2329
Volume :: 192
Issue :: 26
Database :: MEDLINE
Journal :: CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
Publication Type :: Editorial & Opinion
Accession number :: 32601253
Full Text :: https://doi.org/10.1503/cmaj.76076